医学
神秘的
剖腹手术
肝移植
淋巴结切除术
疾病
放射科
外科
移植
内科学
淋巴结
病理
替代医学
作者
Christopher J. Sonnenday
标识
DOI:10.1016/j.suc.2023.09.004
摘要
Hilar cholangiocarcinoma (hCCA) is an infiltrative disease that often presents with locally advanced and/or metastatic disease, with a minority of patients eligible for surgical resection. Select patients with unresectable hCCA, or patients with hCCA in the setting of primary sclerosing cholangitis, with tumors less than 3 cm and no evidence of extrahepatic disease, can be effectively treated with neoadjuvant chemoradiation followed by liver transplantation. Staging laparotomy documenting lack of occult metastatic disease, including a portal lymphadenectomy documenting no nodal metastases, is essential to achieve optimal outcomes. Overall 5 year survival among treated patients is approximately 60%.
科研通智能强力驱动
Strongly Powered by AbleSci AI